Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRV250 for GTN-induced migraine
NCT04201080Phase 1Terminated
- Sponsor
- Trevena, Inc.
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TRV250 in migraine (6 arms), sponsored by Trevena, Inc. Primary endpoint: Proportion of patients with headache rating ≥2 points. Started Nov 2019; status: terminated.
02
Drugs
TRV250
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04201080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201080.